Neurological Sciences

, Volume 40, Issue 1, pp 113–120 | Cite as

Vinpocetine regulates levels of circulating TLRs in Parkinson’s disease patients

  • Zhang PingEmail author
  • Wu Xiaomu
  • Xie Xufang
  • Shao LiangEmail author
Original Article



The pathogenesis of Parkinson’s disease (PD) is complex; it includes mitochondrial dysfunction, oxidative stress, and neuroinflammation. Notably, Toll-like receptors (TLRs) may activate inflammatory or anti-inflammatory responses in Parkinson’s disease. Vinpocetine has been tested as an anti-inflammatory in both animal and in vitro research. Thus, it is important to test whether the anti-inflammatory properties of vinpocetine may have a protective effect in PD patients.


Eighty-nine Parkinson’s disease patients and 42 healthy controls were recruited for this study. All patients were randomly assigned to either the traditional therapy group (T PD group, n = 46) or the vinpocetine group (V PD group, n = 43), in a blinded manner. Both treatments were administered for 14 days.


Administration of vinpocetine reduced mRNA levels of TLR2/4, as well as protein levels of the downstream signalling molecules, MyD88 and NF-κB; moreover, it lowered the expression levels of serum inflammatory cytokines, TNF-α and MCP-1. Notably, vinpocetine increased TLR3 mRNA levels, as well as protein levels of the downstream signalling molecules TRIF-β and IRF-3, and serum levels of the anti-inflammatory cytokines IL-10 and IL-8. Furthermore, vinpocetine produced a robust increase in the Mini Mental State Examination score, compared to that achieved by using levodopa therapy.


Vinpocetine treatment may exhibit anti-inflammatory activity and alleviate cognitive impairment.


Parkinson’s disease TLRs Vinpocetine Neuroinflammation 


Funding information

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: the National Natural Science Foundation of China (Grant No. 81300115) to Liang Shao.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

10072_2018_3592_MOESM1_ESM.docx (16 kb)
ESM 1 (DOCX 15 kb)


  1. 1.
    Shephard F, Greville-Heygate O, Liddell S, Emes R, Chakrabarti L (2016) Analysis of Mitochondrial haemoglobin in Parkinson’s disease brain. Mitochondrion 29:45–52CrossRefGoogle Scholar
  2. 2.
    Bolner A, Micciolo R, Bosello O, Nordera GP (2016) A panel of oxidative stress markers in Parkinson’s disease. Clin Lab 62(1–2):105–112PubMedGoogle Scholar
  3. 3.
    Clark LF, Kodadek T (2016) The immune system and neuroinflammation as potential sources of blood-based biomarkers for Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. ACS Chem Neurosci 7(5):520–527CrossRefGoogle Scholar
  4. 4.
    Cappellano G, Carecchio M, Fleetwood T, Magistrelli L, Cantello R, Dianzani U, Comi C (2013) Immunity and inflammation in neurodegenerative diseases. Am J Neurodegener Dis 2(2):89–107PubMedPubMedCentralGoogle Scholar
  5. 5.
    Daniele SG, Béraud D, Davenport C, Cheng K, Yin H, Maguire-Zeiss KA (2015) Activation of MyD88-dependent TLR1/2 signaling by misfolded α-synuclein, a protein linked to neurodegenerative disorders. Sci Signal 8(376):ra45CrossRefGoogle Scholar
  6. 6.
    Noelker C, Morel L, Lescot T, Osterloh A, Alvarez-Fischer D, Breloer M, Henze C, Depboylu C, Skrzydelski D, Michel PP, Dodel RC, Lu L, Hirsch EC, Hunot S, Hartmann A (2013) Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease. Sci Rep 3:1393CrossRefGoogle Scholar
  7. 7.
    Kalinderi K, Bostantjopoulou S, Katsarou Z, Fidani L (2013) TLR9 -1237 T/C and TLR2 -194 to -174 del polymorphisms and the risk of Parkinson's disease in the Greek population: a pilot study. Neurol Sci 34(5):679–682CrossRefGoogle Scholar
  8. 8.
    Zhao J, Han X, Xue L, Zhu K, Liu H, Xie A (2015) Association of TLR4 gene polymorphisms with sporadic Parkinson's disease in a Han Chinese population. Neurol Sci 36(9):1659–1665CrossRefGoogle Scholar
  9. 9.
    Smith GA, Rocha EM, Rooney T, Barneoud P, McLean JR, Beagan J, Osborn T, Coimbra M, Luo Y, Hallett PJ, Isacson O (2015) A Nurr1 agonist causes neuroprotection in a Parkinson’s disease lesion model primed with the toll-like receptor 3 dsRNA inflammatory stimulant poly(I:C). PLoS One 10(3):e0121072CrossRefGoogle Scholar
  10. 10.
    Szilágyi G, Nagy Z, Balkay L, Boros I, Emri M, Lehel S, Márián T, Molnár T, Szakáll S, Trón L, Bereczki D, Csiba L, Fekete I, Kerényi L, Galuska L, Varga J, Bönöczk P, Vas A, Gulyás B (2005) Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study. J Neurol Sci 229-230:275–284CrossRefGoogle Scholar
  11. 11.
    Zhang L, Yang L (2014) Anti-inflammatory effects of vinpocetine in atherosclerosis and ischemic stroke: a review of the literature. Molecules 20(1):335–347CrossRefGoogle Scholar
  12. 12.
    Dastidar SG, Rajagopal D, Ray A (2007) Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs 8(5):364–372PubMedGoogle Scholar
  13. 13.
    Banner KH, Trevethick MA (2004) PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. Trends Pharmacol Sci 25(8):430–436CrossRefGoogle Scholar
  14. 14.
    Fan CK (2006) Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 533(1–3):110–117Google Scholar
  15. 15.
    Stallard N, Miller F, Day S, Hee SW, Madan J, Zohar S, Posch M (2017) Determination of the optimal sample size for a clinical trial accounting for the population size. Biom J 59(4):609–625CrossRefGoogle Scholar
  16. 16.
    Ouchi Y, Yagi S, Yokokura M, Sakamoto M (2009) Neuroinflammation in the living brain of Parkinson’s disease. Parkinsonism Relat Disord 15(Suppl 3):S200–S204CrossRefGoogle Scholar
  17. 17.
    Comi C, Tondo G (2017) Insights into the protective role of immunity in neurodegenerative disease. Neural Regen Res 12(1):64–65CrossRefGoogle Scholar
  18. 18.
    Wu YR, Feng IH, Lyu RK, Chang KH, Lin YY, Chan H, Hu FJ, Lee-Chen GJ, Chen CM (2007) Tumor necrosis factor-alpha promoter polymorphism is associated with the risk of Parkinson’s disease. Am J Med Genet B Neuropsychiatr Genet 144B(3):300–304CrossRefGoogle Scholar
  19. 19.
    Nishimura M, Mizuta I, Mizuta E, Yamasaki S, Ohta M, Kaji R et al (2001) Tumor necrosis factor gene polymorphisms in patients with sporadic Parkinson’s disease. Neurosci Lett 311(1):1–4CrossRefGoogle Scholar
  20. 20.
    Downer EJ, Johnston DG, Lynch MA (2013) Differential role of Dok1 and Dok2 in TLR2-induced inflammatory signaling in glia. Mol Cell Neurosci 56:148–158CrossRefGoogle Scholar
  21. 21.
    Ruiz-Miyazawa KW, Pinho-Ribeiro FA, Zarpelon AC, Staurengo-Ferrari L, Silva RL, Alves-Filho JC, Cunha TM, Cunha FQ, Casagrande R, Verri WA Jr (2015) Vinpocetine reduces lipopolysaccharide-induced inflammatory pain and neutrophil recruitment in mice by targeting oxidative stress, cytokines and NF-κB. Chem Biol Interact 237:9–17CrossRefGoogle Scholar
  22. 22.
    Wang YC, Lin S, Yang QW (2011) Toll-like receptors in cerebral ischemic inflammatory injury. J Neuroinflammation 8:134CrossRefGoogle Scholar
  23. 23.
    Fellner L, Irschick R, Schanda K, Reindl M, Klimaschewski L, Poewe W, Wenning GK, Stefanova N (2013) Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia. Glia 61:349–360CrossRefGoogle Scholar
  24. 24.
    McCabe K, Concannon RM, McKernan DP, Dowd E (2017) Time-course of striatal Toll-like receptor expression in neurotoxic, environmental and inflammatory rat models of Parkinson’s disease. J Neuroimmunol 310:103–106CrossRefGoogle Scholar
  25. 25.
    Jeon KI, Xu X, Aizawa T, Lim JH, Jono H, Kwon DS, Abe J, Berk BC, Li JD, Yan C (2010) Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc Natl Acad Sci U S A 107(21):9795–9800CrossRefGoogle Scholar
  26. 26.
    Dzamko N, Gysbers A, Perera G, Bahar A, Shankar A, Gao J, Fu Y, Halliday GM (2017) Toll-like receptor 2 is increased in neurons in Parkinson’s disease brain and may contribute to alpha-synuclein pathology. Acta Neuropathol 133(2):303–319CrossRefGoogle Scholar
  27. 27.
    Kim C, Rockenstein E, Spencer B, Kim HK, Adame A, Trejo M, Stafa K, Lee HJ, Lee SJ, Masliah E (2015) Antagonizing neuronal toll-like receptor 2 prevents synucleinopathy by activating autophagy. Cell Rep 13(4):771–782CrossRefGoogle Scholar
  28. 28.
    Filgueiras CC, Krahe TE, Medina AE (2010) Phosphodiesterase type 1 inhibition improves learning in rats exposed to alcohol during the third trimester equivalent of human gestation. Neurosci Lett 473(3):202–207CrossRefGoogle Scholar
  29. 29.
    Molnár P, Gaál L, Horváth C (1994) The impairment of long-term potentiation in rats with medial septal lesion and its restoration by cognition enhancers. Neurobiology (Bp) 2(3):255–266Google Scholar
  30. 30.
    Hindmarch I, Fuchs HH, Erzigkeit H (1991) Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol 6(1):31–43CrossRefGoogle Scholar
  31. 31.
    Patyar S, Prakash A, Modi M, Medhi B (2011) Role of vinpocetine in cerebrovascular diseases. Pharmacol Rep 63(3):618–628CrossRefGoogle Scholar
  32. 32.
    Gupta S, Singh P, Sharma BM, Sharma B (2015) Neuroprotective effects of agomelatine and vinpocetine against chronic cerebral hypoperfusion induced vascular dementia. Curr Neurovasc Res 12(3):240–252CrossRefGoogle Scholar
  33. 33.
    Tombaugh TN (2005) Test-retest reliable coefficients and 5-year change scores for the MMSE and 3MS. Arch Clin Neuropsychol 20(4):485–503CrossRefGoogle Scholar
  34. 34.
    Manza P, Schwartz G, Masson M, Kann S, Volkow ND, Li CR, Leung HC (2018) Levodopa improves response inhibition and enhances striatal activation in early-stage Parkinson's disease. Neurobiol Aging 66:12–22CrossRefGoogle Scholar
  35. 35.
    Thomas I, Alam M, Nyholm D, Senek M, Westin J (2018) Individual dose-response models for levodopa infusion dose optimization. Int J Med Inform 112:137–142CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of NeurologyJiangxi Provincial People’s HospitalNanchangChina
  2. 2.Department of CardiologyJiangxi Provincial People’s HospitalNanchangChina

Personalised recommendations